Halberd Corporation Selects University Research Partner

Rhea-AI Summary

Halberd Corp. (OTC PINK: HALB) announced the successful completion of a partnership with a major research university to develop compounds for its patented extracorporeal treatment for Covid-19. The contract terms are finalized, and signatures are in process, with more details to be released soon. Halberd holds exclusive rights to multiple provisional patents related to Covid-19 treatments. The company is debt-free and compliant with OTC Market reporting requirements.

Positive

• Successful partnership with a major research university to develop Covid-19 treatment compounds.
• Exclusive rights to multiple provisional patents for Covid-19 treatment technologies.
• Debt-free status and compliance with OTC Market reporting requirements.

Negative

• Uncertainty regarding the overall impact of the Covid-19 pandemic on future operations.
• Potential risks due to SEC targeting companies claiming involvement in COVID-19 initiatives.

JACKSON CENTER, PA / ACCESSWIRE / August 27, 2020 / Halberd Corp. (OTC PINK:HALB) is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd's patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and signatures on the contract reflecting the agreed terms, is in process. Details will be released shortly.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly-traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Title	Application No.	Filing Date	Priority	Status
Method for Treating and Curing Covid-19 Infection	US 62/989981	03/16/2020	n/a	Provisional application Pending
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients	US 63/007207	04/08/2020	n/a	Provisional application Pending
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus	US 63/013104	4/21/2020	n/a	Provisional application Pending

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/603572/Halberd-Corporation-Selects-University-Research-Partner

FAQ

What is Halberd Corp.'s recent university partnership about?

Halberd Corp. partnered with a major research university to develop compounds for its Covid-19 treatment technology.

How is Halberd Corp. positioned in terms of patents for Covid-19 treatment?

Halberd holds exclusive rights to several provisional patents related to the treatment and curing of Covid-19.

What does Halberd Corp.'s debt situation look like?

Halberd Corp. is currently debt-free.

Is Halberd Corp. compliant with OTC Market requirements?

Yes, Halberd Corp. is in full compliance with OTC Market reporting requirements.

What risks does Halberd Corp. face regarding its COVID-19 initiatives?

Halberd may face scrutiny from the SEC due to its claims about Covid-19 treatments, which poses a risk to investors.